National Asset Management, Inc. Paratek Pharmaceuticals, Inc. Transaction History

National Asset Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$1.67 - $2.51 $27,054 - $40,662	-16,200 Reduced 35.06%	30,000 $56,000
Q1 2022 May 02, 2022	BUY	$2.94 - $4.77 $33,810 - $54,854	11,500 Added 33.14%	46,200 $138,000
Q4 2021 Jan 28, 2022	SELL	$4.07 - $5.3 $24,420 - $31,800	-6,000 Reduced 14.74%	34,700 $156,000
Q3 2021 Nov 16, 2021	BUY	$4.7 - $7.24 $56,870 - $87,604	12,100 Added 42.31%	40,700 $198,000
Q2 2021 Aug 10, 2021	BUY	$6.81 - $10.93 $194,766 - $312,598	28,600 New	28,600 $196,000
Q2 2020 Jul 31, 2020	SELL	$2.97 - $5.22 $35,046 - $61,596	-11,800 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$2.67 - $4.97 $18,690 - $34,790	-7,000 Reduced 37.23%	11,800 $38,000
Q4 2019 Feb 10, 2020	BUY	$2.93 - $4.5 $13,771 - $21,150	4,700 Added 33.33%	18,800 $76,000
Q3 2019 Nov 12, 2019	BUY	$3.08 - $5.76 $43,428 - $81,216	14,100 New	14,100 $61,000
Q2 2019 Aug 05, 2019	SELL	$3.47 - $6.32 $45,110 - $82,160	-13,000 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$4.8 - $11.6 $4,800 - $11,600	1,000 Added 8.33%	13,000 $67,000
Q3 2018 Nov 08, 2018	BUY	$9.05 - $10.95 $108,600 - $131,400	12,000 New	12,000 $117,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.